- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05876962
The Impact of Rapid Diagnostic Methods in the Diagnosis of Fungal Infections in Intensive Care Units of Assiut University Hospital
January 29, 2024 updated by: Sara salah abd El mawgoud, Assiut University
The diagnosis of invasive fungal disease remains challenging in the clinical laboratory.
The use of matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) for the identification of filamentous fungi as well as its application for antifungal resistance testing and strain typing Will be evaluated.
Study Overview
Status
Not yet recruiting
Conditions
Detailed Description
Fungal infections are life-threatening opportunistic infections that have emerged as a major cause of morbidity and mortality in critically ill patients.
Yeast infections,mainly Candida spp., remain much more frequent than mold infections.
Among mold infections, Aspergillus spp.
represent the most frequently isolated filamentous fungi in these circumstances .Candida species are the most common cause of nosocomial fungal infections and the fourth most common source of hospital-acquired infections.
Candidiasis is an infection caused by Candida, mostly limited to the skin, nails and mucous membranes.
However, it can cause serious systemic infections.
Candidiasis is an opportunistic infection occurring in presence of predisposing factors like extensive and prolonged administration of broad-spectrum antimicrobials, corticosteroids, immunosuppressive agents and cytotoxic drugs, diabetes mellitus, HIV, chronic renal failure, haemodialysis, renal transplantation or indwelling urinary catheter.The pathogenicity of Candida spp. is related to a combination of microbial factors such as their ability to grow at 37°C, polymorphism, biofilm formation, hydrolytic enzyme secretion, and phenotypic switching.
Candida species are identified by different phenotypic methods including examination of their morphological features, analysis of their ability of carbohydrates assimilation and/or fermentation, and their ability of assimilating different nitrogen compounds.
Numerous antifungal classes are used to treat Candida infections; polyenes, azoles, echinocandins and allylamines.
These antifungals are used with varying efficacy depending on the type, site of infection and the susceptibility of different Candida species.
Azoles are the most frequently used antifungal drugs to treat Candida infections as they achieve high success rates even over short durations of therapy.
However, resistance among previously susceptible Candida species has emerged following the expanded use of antifungal agents.
Antifungal susceptibility testing methods including broth dilution, disk diffusion and E test are now available with species-specific breakpoints developed by The Clinical and Laboratory Standards Institute (CLSI) for multiple antifungal agents.
Study Type
Observational
Enrollment (Estimated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: sara salah
- Phone Number: 01092127787
- Email: fawazsara91@gmail.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients of all age group and both sex with clinically suspected fungal infection at intensive care units of Assiut university hospital will be included
Description
Inclusion Criteria:
- Patients of all age group and both sex with clinically suspected fungal infection at intensive care units of Assiut university hospital will be included.
Exclusion Criteria:
- -Patients who are on antifungal treatment and refuse to take part will be excluded from the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phenotypically identify percentage of different fungal infections isolated from various clinical specimens in intensive care units. and Assess their antifungal susceptibility pattern.
Time Frame: baseline
|
Assess the accuracy of Maldi-TOF in diagnosis of fungal infections
|
baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: asmaa omar, professor
- Study Chair: mohamed zakaria, professor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Colombo AL, de Almeida Junior JN, Slavin MA, Chen SC, Sorrell TC. Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer. Lancet Infect Dis. 2017 Nov;17(11):e344-e356. doi: 10.1016/S1473-3099(17)30304-3. Epub 2017 Jul 31.
- Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers. 2018 May 11;4:18026. doi: 10.1038/nrdp.2018.26.
- Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence. 2013 Feb 15;4(2):119-28. doi: 10.4161/viru.22913. Epub 2013 Jan 9.
- Neppelenbroek KH, Seo RS, Urban VM, Silva S, Dovigo LN, Jorge JH, Campanha NH. Identification of Candida species in the clinical laboratory: a review of conventional, commercial, and molecular techniques. Oral Dis. 2014 May;20(4):329-44. doi: 10.1111/odi.12123. Epub 2013 May 16.
- Vandeputte P, Ferrari S, Coste AT. Antifungal resistance and new strategies to control fungal infections. Int J Microbiol. 2012;2012:713687. doi: 10.1155/2012/713687. Epub 2011 Dec 1.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
January 1, 2024
Primary Completion (Estimated)
May 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
May 17, 2023
First Submitted That Met QC Criteria
May 17, 2023
First Posted (Actual)
May 26, 2023
Study Record Updates
Last Update Posted (Actual)
January 30, 2024
Last Update Submitted That Met QC Criteria
January 29, 2024
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Diagnosis of fungal infection
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fungal Infection
-
Radboud University Medical CenterCompletedInvasive Fungal InfectionNetherlands
-
People's Hospital of Zhengzhou UniversityCompletedAn Individualized Administration Research of Voriconazole Based on CYP2C19 Gene Polymorphism and TDMInvasive Fungal InfectionChina
-
Grupo de Estudio de Infecciones en TransplantadosMerck Sharp & Dohme LLCUnknownLiver Transplantation | Fungal InfectionSpain
-
Bayside HealthMerck Sharp & Dohme LLCUnknownFungal InfectionAustralia
-
Daping Hospital and the Research Institute of Surgery...RecruitingInvasive Fungal Infection | Neonatal Infection | Plasma AdministrationChina
-
University of PittsburghSchering-PloughTerminatedFungal InfectionUnited States
-
Merck Sharp & Dohme LLCCompleted
-
University of PittsburghAstellas Pharma US, Inc.Completed
-
Ruijin HospitalMerck Sharp & Dohme LLCUnknown
-
Merck Sharp & Dohme LLCRecruitingInvasive Fungal InfectionIsrael, United States, Belgium, Greece, Peru, Poland, Mexico, Russian Federation